Lamzede (velmanase alfa-tycv)

Lamzede is covered for treatment of non‑central nervous system manifestations of alpha‑mannosidosis in adults and children but is not indicated for CNS manifestations. Coverage requires alpha‑mannosidase activity <10% in blood leukocytes, confirmation of biallelic pathogenic MAN2B1 variants, clinical non‑CNS manifestations, prescription by or in consultation with a geneticist/endocrinologist/metabolic or lysosomal disorder specialist, documentation of enzyme and genetic testing and clinical findings, and is authorized for 12 months at the recommended dose of 1 mg/kg IV weekly.

"Treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.